BioSpace News Archive

Britten Devereux, CEO and Chief Clinician at D’Amore Healthcare, will guest-host Answers for the Family on August 26, 2019.

August 27th Hearing of Rare Disease California Caucus and CAL RARE to Tackle Policy Issues Facing Patients Living with Rare Disease; HAAF Sponsors Resolution to Declare September 29th as Cardiac Amyloidosis Day

PharPoint Research Inc., a contract research organization (CRO) focused on bringing pharmaceutical and biotechnological products to market through a range of services, announced it is expanding offices in both Durham and Wilmington, North Carolina.

AMNICELL, a biotech company focusing on research and development of amniotic fluid stem cells, today announced that Helen Ljungdahl Round has been appointed as CEO, effective July 1, 2019.

C3® International, Inc., a biopharmaceutical company that has played a leadership role in the emerging cannabinoid therapeutics health sector, today officially announced that HRH Dr. Percy Tamayo is joining the company in the role of Vice President.

Health Canada is advising Canadians that the following products may pose serious health risks. For more information, including what Canadians should do, visit the online safety alert.

Masimo announced that in a randomized controlled study involving 150 ICU patients recently published as a letter in Intensive Care Medicine, researchers investigated whether monitoring with Masimo ORi™ could reduce the time critically ill patients spend with moderate hyperoxia, compared to monitoring with oxygen saturation alone.

Arcadia Biosciences, Inc. announced a binding term sheet agreement with Arista Cereal Technologies and Bay State Milling Company for commercialization of its high fiber resistant starch wheat in key wheat markets, including North America, Europe and parts of Asia.

Maxar Technologies, a trusted partner and innovator in Earth Intelligence and Space Infrastructure, announced that members of senior management will present at the following investor conferences:

Bristol-Myers Squibb Company announced that Celgene Corporation, in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen under which Amgen would acquire the global rights to OTEZLA® for $13.4 billion in cash.